Remove 2019 Remove Compounding Remove FDA
article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

FDA 129
article thumbnail

7 health benefits of raspberry leaf tea

The Checkup by Singlecare

Red raspberry leaves are rich in tannins (a chemical compound) and flavonoids (a plant pigment), which both have antioxidant properties, according to research in Antioxidants journal. Provides antioxidants Its no secret that raspberries are a good source of antioxidants, such as vitamin C. But what about the leaves?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT

As of 2019, about 1.9 Diabetic patients will now have easier access to insulin after the FDA approved an Eli Lilly biosimilar as interchangeable with the biologic drug , Bloomberg News notes.  Rezvoglar, The agency issued 62 warning letters and 23 import alerts related to drugs, excluding compound-related actions.

FDA 98
article thumbnail

Is Repatha a statin?

The Checkup by Singlecare

Some options include : Repatha (evolocumab) is a brand-name medication that is FDA approved to lower cholesterol and reduce the risk of heart attacks and strokes, by helping to restore blood flow to the heart in individuals with heart disease. It first gained FDA approval in 2015.

Dosage 98
article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Although some psychedelics have a long history in traditional medicine, regulatory agencies must evaluate psychedelic compounds the same way they assess any other drug. Psychedelic compounds are assessed by regulators the same way as any other drug. This US pathway offers early-phase benefits, including greater FDA collaboration.

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

billion takeover of Clementia Pharma in 2019 – and erosion of its sales for top-selling acromegaly and neuroendocrine tumour therapy Somatuline (lanreotide). “Furthermore, we are excited to bring on board epigenetic expertise and the SETD2 inhibitor, as well as several preclinical compounds into our portfolio.”

article thumbnail

The lingering menace of diethylene glycol / ethylene glycol adulteration

European Pharmaceutical Review

The 1938 law effectively changed the focus of the Food and Drug Administration (FDA) from a policing agency to a regulatory agency tasked with overseeing the safety evaluation of new drug products. There is now global awareness of this issue and FDA issued a guidance note on the problem in 2007. 5 Both compounds are limited to ≤0.1